BIO-Europe 2010 Exhibitor Profiles

MUNICH--(BUSINESS WIRE)-- BIO-Europe 2010 takes place Nov. 15-17, 2010 at the International Congress Centre in Munich.

Business Wire is the official newswire and online press kit service for BIO-Europe 2010. Breaking news releases, online press kits, and multimedia are available at TradeshowNews.com, Business Wire's trade show, conference, and event news resource.

Listed below are exhibitor profiles.

Company:     Amakem NV
Media Contact: Jack Elands
Phone: 32 474 828 580
E-mail: [email protected]
Web: www.amakem.com
 
Amakem NV is a biopharmaceutical company developing safe and effective kinase inhibitors for the treatment of auto-immune and inflammatory diseases, such as COPD, glaucoma and inflammatory bowel disease. Amakem is using its "Localized Drug Action" platform to significantly limit or avoid systemic exposure, which would otherwise result in side effects. The company is currently progressing its advanced COPD leads towards clinical candidates to then obtain proof of mechanism in functional phase 1 clinical studies.
 
Amakem is located in the life sciences incubator “BioVille” on the campus of the University of Hasselt in Belgium.
 
 
Company: Eurand Pharmaceutical Technologies
Ticker Symbol & Exchange: EURX
Media Contact: Sarah Kuhn
Phone: 267-759-9361
E-mail: [email protected]
Web: www.eurand.com
 
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products using our proprietary drug formulation technologies.
 

Eurand has had six partnered and proprietary products approved by the FDA since 2001 and has a pipeline of product candidates in development for ourselves and collaboration partners.

 
Eurand provides one of the broadest, well-validated portfolios of drug delivery technologies for development of Rx and OTC formulations. Our technologies can be used as innovative and effective life-cycle management tools that can prolong the market life of products.
 
 
Company: Genometrica Ltd.
Booth: 16
Media Contact: Maria Labunskaya
Phone: 41 44 5868858
E-mail: [email protected]
Web: www.genometrica.com
 
Genometrica Ltd. supplies new generation equipment for basic types of molecular diagnostic assays based on laser-induced fluorescence. The equipment has been designed, taking into account the specific needs of small labs and researchers. Unique technical solutions provide a combination of exceptionally high accuracy, flexibility, ease of maintenance, low price and low cost of consumables.
 
 
Company: PATHEON
Booth: 64 (Level 1, Foyer)
Ticker Symbol & Exchange: PTI
Media Contact: Benjamin Beauvalot
Phone: 919.226.3200
E-mail: [email protected]
Web: www.patheon.com
 
Patheon Inc. is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.
 
Patheon’s comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization.
 
Patheon, with its integrated network, strives to ensure that customer products can be launched with confidence anywhere in the world.
 

About Business Wire

Business Wire, a Berkshire Hathaway company, is utilized by tens of thousands of member companies and organizations worldwide to functionally enhance and communicate investor relations and public relations content to target audiences. As a recognized disclosure service in the United States, Canada and a dozen European countries, Business Wire facilitates the simultaneous flow of market-moving press releases from corporations to financial markets and their audiences, including regulatory authorities, media, investors, financial information systems and consumer news services. Business Wire also handles XBRL tagging, document formatting and regulatory filing into EDGAR, SEDAR, FSA and other systems.

Communications professionals turn to Business Wire to optimize and issue press releases, photos and multimedia to news organizations, journalists, trade publications, search engines, and individuals, with full-text posting to web sites, online services and databases. A range of distribution options enables members to target by geography, industry, news theme and audience demographics.

Founded in 1961, Business Wire has dual headquarters in San Francisco and New York, with 31 bureaus in cities including Los Angeles, Chicago, Boston, Miami, Paris, Frankfurt, London, Brussels, Tokyo, Toronto and Sydney and reciprocal offices throughout the world. Business Wire's patented NX data platform supports XML, XHTML and XBRL code that enhances news release interactivity, social media sharing and search engine optimization. More information about Business Wire and its services is located on its website at www.BusinessWire.com.



CONTACT:

Business Wire
Global Event Services
310-820-9473
http://www.businesswire.com
http://www.tradeshownews.com
twitter: @tradeshownews
facebook: http://www.facebook.com/TradeshowNews

KEYWORDS:   Europe  Germany

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.